Month: August 2020

SHENZHEN, China, Aug. 06, 2020 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading online consumption and consumer finance platform for educated young professionals in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2020 before the U.S. market opens on Tuesday, August 18, 2020.The Company’s management will host an earnings conference call at 7:00 AM U.S. Eastern time on August 18, 2020 (7:00 PM Beijing/Hong Kong time on August 18, 2020).Participants who wish to join the conference call should register online at:http://apac.directeventreg.com/registration/event/6562599Please note the Conference ID number of 6562599.Once registration is completed, participants will receive the dial-in information for...

Geneva, Switzerland, August 6, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will participate in the BTIG Virtual Biotechnology Conference taking place on August 10 – 11, 2020.Mr. Dyer will participate and present Addex on August 10, 2020 at 10:30 AM ET. You can follow the event by following this link.Mr. Dyer will also be available for one-on-one meetings during the conference. Meetings can be requested via the BTIG virtual conference system for those who registered to participate.About Addex TherapeuticsAddex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs...

On target despite global disruptionAugust 6, 2020HighlightsEffective response to COVID-19 and oil price crisesSuccessfully maintaining focus on health and safety of staff and business continuityAdapting the organization to ensure flexibility, performance and competitivenessFinancial results in line with expectation2020 Directional1 EBITDA guidance increased from “around” to “above” US$900 million2020 Directional revenue guidance maintained at “around” US$2.3 billionThe 2020 Half Year Results and Interim Financial Statements are published on the Company’s website under https://www.sbmoffshore.com/investor-relations-centre/financial-information/financial-results/half-year-results/.Bruno Chabas, CEO of SBM Offshore, commented:“Over the last six months, SBM Offshore has successfully navigated a challenging period, having mitigated the COVID-19...

Saint-Herblain (France), August 6, 2020 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the appointment of Juan Carlos Jaramillo, MD as Chief Medical Officer and member of the Management Board starting 1st October 2020. Juan Carlos will succeed Wolfgang Bender, MD, PhD who will retire after a hand-over period, at the end of October 2020.Dr. Juan Carlos Jaramillo has a broad international experience, strong expertise in Medical Affairs and Clinical Development that includes vaccines, as well as Global Market Access. Due to his diverse pharma exposure, he has an in-depth business understanding and a strong track-record of success across a wide range of settings, therapeutic areas and geographies. He has worked in various pharmaceutical/biotech organizations,...

Saint-Herblain (France), 6 août 2020 – Valneva SE (“Valneva”), société spécialisée dans les vaccins contre des maladies générant d’importants besoins médicaux, a annoncé aujourd’hui la nomination de Juan Carlos Jaramillo, MD, comme Directeur Médical et membre du directoire de Valneva à compter du 1er Octobre 2020. Juan Carlos succèdera à Wolfgang Bender, MD, PhD, qui prendra sa retraite fin octobre 2020, après une période de transition.Le Dr. Juan Carlos Jaramillo possède une très grande expérience internationale ainsi qu’une forte expertise en matière d’affaires médicales et de développement clinique, qui inclut les vaccins ainsi que l’accès aux marchés mondiaux. Grâce à une expérience diversifiée dans le secteur pharmaceutique, le Dr Jaramillo a une connaissance approfondie du monde des affaires et a connu de nombreuses réussites dans...

 Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroidsPhase 3 data from PRIMROSE 2 trial demonstrated sustained efficacy and continued safety over 52 weeks of treatment with linzagolix,including bone mineral density changes   Phase 3 trial results support the advancement of linzagolix 100 mg without add-back therapy and 200 mg with add-back therapy doses to regulatory submissions planned for Q4:20/H1:21 in Europe/U.S.Actively discussing commercial partnership to maximize linzagolix best-in-class potentialOBE022 Phase 2 PROLONG trial results on track for Q4:20YuYuan Bioscience Technology submitted pre-IND meeting request for nolasiban development in China                         GENEVA, Switzerland and BOSTON, MA (August 6, 2020) – ObsEva SA (NASDAQ:...

Press ReleaseOutside trading hours – Regulated information*Brussels, 6 August 2020 (07.00 a.m. CEST)KBC Group: Second-quarter result of 210 million eurosThe quarter under review started with the society in lockdown due to the coronavirus crisis. Over and above the human suffering caused by the pandemic itself, this also triggered unprecedented economic consequences. Even though society is now gradually reopening, it is clear that the coronavirus crisis will have a significant impact, especially in particular sectors. However, the various relief measures implemented in our home countries may help contain the overall impact going forward. Obviously, the long-term impact on the economy also depends on the occurrence and intensity of new outbreaks of the virus now and in the coming months.Since the start of the coronavirus crisis, we...

Nordecon Group’s financial results of the first half of 2020 as compared to the same period from the last year are characterised by substantial growth in revenue, improved gross and operating margins as well as exchange rate losses related to Ukranian hryvnia. Also, the order book has increased year on year with new substantial contracts signed in July adding to this figure. At the same time, the volume of private orders has decreased significantly, which has been directly influenced by the worldwide COVID-19 crisis and the rapid deterioration of economic conditions. This has resulted in increased price pressure put on the main contractors by the demand side, whereas on the other side there has still been no expected decrease in the input prices. In these circumstances there is strong pressure on profit margins.Condensed consolidated...

PersberichtBuiten beurstijd – gereglementeerde informatie*Brussel, 6 augustus 2020 (07u00 CEST)KBC Groep: Resultaat tweede kwartaal van 210 miljoen euroHet tweede kwartaal begon met de lockdown van de samenleving als gevolg van de coronacrisis. Naast het menselijke leed dat de pandemie zelf heeft veroorzaakt, bracht dat ook ongekende economische gevolgen met zich mee. Hoewel de samenleving nu geleidelijk aan weer opent, is het duidelijk dat de impact van de coronacrisis significant zal zijn, zeker in bepaalde sectoren. De verschillende steunmaatregelen die werden genomen in onze thuismarkten, kunnen evenwel helpen om de totale impact te beperken. Het is duidelijk dat de langetermijngevolgen voor de economie ook afhangen van nieuwe uitbraken van het virus en de intensiteit ervan, nu en in de komende maanden.Sinds het begin van de coronacrisis...